Related Experiment Video

Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Exploiting p70 S6 kinase as a target for ovarian cancer

Carman K M Ip1, Alice S T Wong

  • 1University of Hong Kong, School of Biological Sciences, 4S-14 Kadoorie Biological Sciences Building, Pokfulam Road, Hong Kong, China.

Expert Opinion on Therapeutic Targets
|May 9, 2012
PubMed
Abstract

Insights

Blocking p70 S6 kinase (p70(S6K)), a key driver in ovarian and other cancers, shows promise for new anticancer treatments. Targeting p70(S6K) offers a potential therapeutic strategy by inhibiting its expression or activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • p70 S6 kinase (p70(S6K)) is highly active in ovarian and various cancers.
  • p70(S6K) plays a critical role in cancer hallmarks.
  • Inhibition of p70(S6K) is a potential anticancer strategy.

Purpose of the Study:

  • To review p70(S6K) regulation and its role in ovarian cancer initiation and progression.
  • To explore the emerging role of p70(S6K) in cell migration and tumor metastasis.
  • To summarize current therapeutic strategies targeting p70(S6K).

Main Methods:

  • Review of molecular mechanisms governing p70(S6K) regulation.
  • Analysis of p70(S6K)'s tumorigenic effects and substrates.
  • Assessment of existing drugs targeting p70(S6K).

Main Results:

  • p70(S6K) is implicated in cancer initiation, progression, and metastasis.
  • Understanding p70(S6K) substrates and interacting proteins is crucial.
  • Current targeted agents for p70(S6K) are under investigation.

Conclusions:

  • Targeting p70(S6K) with inhibitors, microRNAs, or natural compounds is a promising therapeutic avenue.
  • Further research into p70(S6K) biology is warranted for novel cancer therapies.
  • p70(S6K) targeting offers new directions for cancer treatment and investigation.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...